A detailed history of Engineers Gate Manager LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 84,537 shares of SAGE stock, worth $459,881. This represents 0.01% of its overall portfolio holdings.

Number of Shares
84,537
Previous 53,299 58.61%
Holding current value
$459,881
Previous $578,000 5.36%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.02 - $13.08 $219,290 - $408,593
31,238 Added 58.61%
84,537 $609,000
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $321,568 - $544,052
30,394 Added 132.7%
53,299 $578,000
Q1 2024

May 15, 2024

BUY
$18.62 - $26.95 $199,662 - $288,984
10,723 Added 88.02%
22,905 $429,000
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $208,312 - $271,171
12,182 New
12,182 $263,000
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $786,171 - $1.15 Million
19,340 New
19,340 $909,000
Q2 2022

Aug 15, 2022

BUY
$27.52 - $37.99 $912,398 - $1.26 Million
33,154 Added 388.68%
41,684 $1.35 Million
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $261,956 - $389,906
8,530 New
8,530 $282,000
Q3 2021

Nov 15, 2021

SELL
$40.26 - $57.37 $728,464 - $1.04 Million
-18,094 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $992,998 - $1.43 Million
18,094 New
18,094 $1.03 Million
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $206,801 - $313,998
-5,028 Closed
0 $0
Q2 2020

Aug 17, 2020

SELL
$25.95 - $43.15 $166,702 - $277,195
-6,424 Reduced 56.1%
5,028 $209,000
Q1 2020

May 15, 2020

SELL
$26.15 - $77.24 $75,155 - $221,987
-2,874 Reduced 20.06%
11,452 $329,000
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $862,138 - $2.22 Million
14,326 New
14,326 $1.03 Million
Q3 2019

Nov 14, 2019

SELL
$140.29 - $189.96 $168,488 - $228,141
-1,201 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $189,577 - $219,891
1,201 New
1,201 $220,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.